Intas Pharma- Walk-In drives for multiple department - Production, Packing, QA & QC on 4th & 5th May' 2019 @ Pune
Intas Pharma overview:-
Intas is the leading, vertical, global pharmaceutical formulations manufacturing, production and marketing company with the headquarters in India.
Successful and sustained growth of intus is in the clinical implementation of successful and strategic movements in the field of manufacturing, R & D, biotechnology and global action for three decades. By March 31, 2018, Intas has registered 20% CAGR of $ 1.7 billion in the last 5 years. Intus is currently ranked 11th in the Indian pharma market with 2.9% market share.
Enjoy leadership positions in long-term treatments, such as intensive neurology, intake of neurology, cardiovascular, diabetes, oncology, urology, nephrology, rheumatology and gynecology, infertility, gastroenterology, pen management and other major therapeutic segments, in the local market.
In addition to domestic reputation, in more than 80 countries around the world, Ints is also available, such as the strongest sale, marketing and delivery infrastructure in markets like North America, Europe, Central and Latin America, Africa, Australia, New Zealand, Asia-Pacific. As the country of CIS and MENA The Global Policy of the Intents includes alliances with leading global pharma companies for direct product distribution for the development and distribution of products. The company is famous for a range of products in oncology and therapeutic areas based on the EU and other hospitals in the US. After the significant acquisition of Teve's assets, Ints became the leading player in the generic market in the UK.
Intas has been firmly committed to the biology business unit in order to create R & D, manufacturing and marketing capabilities for biotech portfolio. This is the first company to launch the first petitated acquisition technology-based distribution system in the EU (Philagratum and Peg-Philadelphium) and Bioscianer market.
Intus is the fastest growing Indian company in BioSimilar's place. It has 13 business biosimilers, Docetaccel and Paclitaxel. In today's time, Int's continued its research and development in the area of chronic diseases such as cancer (cancer), arthritis, autoimmunity, nephrology, ophthalmology and plasma-generated therapies.
Intas 'success and development intas' have extensive R & D capabilities, its production capabilities and its impact directly with its people. Every year, the company spends about 6-7% of R & D revenue. In addition to creating regular portfolios of generic products, Intash 'R & D' focuses on developing new technology-based products and biology pipelines and has invested 125 million dollars in developing and increasing biozimimar capacity over the last 8 years.
Intas operates fourteen formulation facilities, seven of which are located in India, and in the remaining UK and Mexico. Top global regulators like USFDA, EMA, MHRA, TGA etc. have recognized two major facilities. It is the first company approved by the European Health Authority, India's biological manufacturing facility.
Intas Pharma Profile:-
Core competence in Biosimilar and Plasma-generated products makes intus biologics a Business Unit one of its fastest growing franchisees. Keeping the welfare and wellness of the patient, since 2000, they have been developing bio-therapy, which meets high quality standards and makes available at cheap prices.
To take advantage of R & D's strengths and sophisticated products, Intus Biologics BU has focused on high quality recombinant DNA proteins (RDNA) products and plasma-generated products, such as cancer to address unnecessary medical needs in areas of Oncology, Auto-Immune, Ophthalmology, Nephrology And Plasma Production Promotional Therapy
Intash 'R & D capability and world-class organizations worldwide, it is possible to create a pool of scientists, along with a state-of-the-art technology platform and a strong but specialized product portfolio, which includes 11 commercialized products, 8 mono-colonnels antibodies with 8 RDNA products, and 3 plasma-derived products. In addition, there are 12 products in the company's pipeline. Apart from this, many products have been exported to many countries under various distribution and licensing agreements.
